Healthcare / Medical DevicesTaipei Exchange
$22.80
-0.20 (-0.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $143.3M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
18.8x
↓EV/EBITDA
11.4x
↓ROE
7.3%
↑Gross Margin
29.1%
↓Debt/Equity
0.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.9%
FCF CAGR
-0.7%
FCF margin
4.4%
FCF / Net income
0.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $837.2M · net income $71.2M · FCF $37.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $837.2M | $837.2M | $865.3M | $828.5M | $767.8M |
| Net Income | $71.2M | $71.2M | $93.6M | $85.7M | $48.5M |
| EBITDA | $125.7M | $125.7M | $155.1M | $152.2M | $105.5M |
| EPS | — | — | 1.59 | 1.48 | 0.88 |
| Gross Margin | 29.1% | 29.1% | 31.0% | 28.9% | 23.1% |
| Operating Margin | 7.9% | 7.9% | 10.4% | 10.9% | 5.1% |
| Net Margin | 8.5% | 8.5% | 10.8% | 10.3% | 6.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.49 | 0.49 | 0.50 | 0.64 | 0.93 |
| Current Ratio | 1.82 | 1.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $37.2M | $37.2M | $143.3M | $174.9M | $38.0M |
| Returns | |||||
| ROE | 7.3% | 7.3% | 10.4% | 10.5% | 6.8% |
| Valuation | |||||
| P/E | 18.84 | 18.84 | 17.14 | 18.29 | 25.95 |
| EV/EBITDA | 11.41 | 11.41 | 10.79 | 10.13 | 15.87 |
| P/B | 1.41 | 1.41 | 1.78 | 1.69 | 1.85 |
| Growth & Yield | |||||
| Revenue Growth | -3.3% | -3.3% | 4.4% | 7.9% | — |
| EPS Growth | — | — | 7.6% | 67.0% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.0%
Start / end P/E
n/dx → n/dx
EPS bridge
1.59 → n/d
Residual
-17.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.